Introduction: Selective inhibition of the MAPK pathway with either BRAF or MEK inhibition
has emerged as a key component for the treatment of BRAF-mutant metastatic melanoma …

Selective inhibition of the mitogen activated protein kinase (MAPK) pathway with either
BRAF or MEK inhibition has emerged as the key component for the treatment of BRAF …

Introduction: Selective inhibition of the MAPK pathway with BRAF and MEK inhibitors has
emerged as a key component of the treatment of BRAF-mutant unresectable/locally …

Development of selective inhibitors of BRAF has improved the survival of patients with BRAF-
mutant melanoma. The progression-free survival after treatment with a BRAF inhibitor is …

Treatment with BRAF inhibitors such as vemurafenib or dabrafenib in patients with
advanced BRAFV600 mutated melanoma has shown objective tumor responses in …

Raf-mitogen-activated protein kinase (Raf-MAPK) pathway inhibition with the BRAF
inhibitors vemurafenib and dabrafenib, alone or in combination with a MEK inhibitor, has …

Purpose Preclinical and early clinical studies have demonstrated that initial therapy with
combined BRAF and MEK inhibition is more effective in BRAF V600-mutant melanoma than …

BRAF plus MEK-targeted drugs have out-performed BRAF inhibitor monotherapy in three
randomized phase 3 studies, and such combinations have become a new standard of …

Background Combined BRAF and MEK inhibition, as compared with BRAF inhibition alone,
delays the emergence of resistance and reduces toxic effects in patients who have …

No head-to-head studies exist comparing BRAF inhibitor/MEK inhibitor (BRAFi/MEKi)
combination treatments for BRAF-mutant melanoma. A side-by-side analysis of randomized …